David H Aggen, MD PhD· @Dr_Aggen · X·· 1 day agoScore70
Body · original
VOLGA shows Improved EFS and OS for Durva/EV presented by @tompowles1 #ESMO26 #oncoalert
EFS HR 0.51
OS HR 0.58
pCR rate 44%
224 views · 5 likes · 4 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: David H Aggen, MD PhD · x.com